Monoclonal antibodies specific for the IGF1R ligands [45], as well as inhibitors of PI3 kinase and mTOR, which are activated by signaling through IGF1R, are also effective in neuroblastoma models [46,47,48,49,50,51]. The gene discussed is MTOR; the disease is neuroblastoma.